American Cancer Society Research Professor; Interim Chair, Department of Microbiology and Immunology; and Professor, Cancer Research Institute, UCSF
Leader, Cancer and Immunity Program, UCSF Helen Diller Family Comprehensive Cancer Center
Member, Biomedical Sciences Graduate Program (BMS), Herbert Boyer Program in Biological Sciences (PIBS), and Immunology Graduate Program, UCSF
| CONTACT | |
|
Lewis.Lanier@ucsf.edu Box 0414, UCSF; San Francisco, CA 94143-0414 |
additional websites: |
| EDUCATION | |
|
Virginia Polytechnic Institute & State U., Blacksburg, VA, B.S. (honors), 1975, Microbiology
|
|
| PROFESSIONAL EXPERIENCE | |
|
1981-1988 |
Senior Research Scientist, Becton Dickinson Monoclonal Center, Inc. |
|
1988-1990 |
Associate Research Director, Becton Dickinson Immunocytometry Systems |
|
1991-1992 |
Senior Scientific Staff, Department of Immunology, DNAX Research Institute |
|
1993-1996 |
Associate Director, Department of Human Immunology, DNAX Research Institute |
|
1997-1999 |
Director, Department of Immunobiology, DNAX Research Institute |
|
1999-present |
Professor, Department of Microbiology & Immunology and Cancer Research Institute, University of California, San Francisco |
|
2003-present |
Vice Chair, Department of Microbiology & Immunology, University of California, San Francisco |
| HONORS & AWARDS | |
|
1971 |
Virginia Polytechnic Institute and State University Freshman Science Scholarship |
|
1978-1979 |
National Research Service Award Fellowship, University of North Carolina School of Medicine at Chapel Hill Cancer Research Center |
|
1979-1981 |
Damon Runyon - Walter Winchell Cancer Fund Postdoctoral Fellowship |
|
2001 |
American Association of Immunologists Distinguished Service Award |
|
2002 |
William B Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute, New York |
|
2003 |
American Cancer Society Research Professorship |
|
2005 |
American Society for Histocompatibility and Immunogenetics Rose Payne Award |
|
2006 |
NIH Merit Grant Award |
| SELECTED PUBLICATIONS | |
|
(selected from more than 300) | |
|
Lanier, L.L., M. Lynes, G. Haughton and P.J. Wettstein. 1978. Novel type of murine B cell lymphoma. Nature 271:554. | |
|
Allison, J.P. and L.L. Lanier. 1985. Identification of antigen receptor-associated structures on murine T cells. Nature 314:107. | |
|
Lanier, L.L. and A. Weiss. 1986. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature 324:268. | |
|
Lanier, L.L., S. Cwirla, G. Yu, R. Testi and J.H. Phillips. 1989. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science 246:1611-1613. | |
|
Lanier, L.L., G. Yu and J.H. Phillips. 1989. Co-association of CD3z with receptor (CD16) for IgG on human natural killer cells. Nature 342:803. | |
|
Azuma, M., D. Ito, H. Yagita, K. Okumura, J.H. Phillips, L.L. Lanier and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76. | |
|
Phillips, J.H., J. Gumperz, P. Parham and L.L. Lanier. 1995. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science 268:403-405. | |
|
Lanier, L.L., B.C. Corliss, J. Wu, C. Leong and J.H. Phillips. 1998. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703. | |
|
Braud, V.M., D.S.J. Allan, C.A. O'Callaghan, K. Soderstrom, A. D'Andrea, G.S. Ogg, S. Lazetic, N.T. Young, J.I. Bell, J.H. Phillips, L.L. Lanier and A.J. McMichael. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 391:795-799. | |
|
Bauer, S., V. Groh, J. Wu, A. Steinle, J.H. Phillips, L.L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729. | |
|
Wu, J., Y. Song, A.B.H. Bakker, S. Bauer, T. Spies, L.L. Lanier, and J.H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730. | |
|
Paloneva, J., M. Kestila, J. Wu, A. Salminen, T. Bohling, V. Ruotsalainen, P. Hakola, A.B.H. Bakker, J.H. Phillips, P. Pekkarinen, L.L. Lanier, T. Timonen, and L. Peltonen. 2000. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nature Genetics 25:357-361. | |
|
Shibuya, A, N. Sakamoto, Y. Shimizu, K. Shibuya, M. Osawa, T. Hiroyama, H.J. Eyre, G.R. Sutherland, Y. Endo, T. Fujita, T. Miyabayashi, S. Sakano, T. Tsuji, E. Nakayama, J.H. Phillips, L.L. Lanier, and H. Nakauchi. 2000. Fcα/μ receptor mediates endocytosis of IgM-coated microbes. Nature Immunology 1:441-446. | |
|
Lanier, L.L. 2001. On guard - activating NK cell receptors. Nature Immunology 2:23-27. | |
|
Cerwenka, A., A.B.H. Bakker, T. McClanahan, J. Wagner, J. Wu, J.H. Phillips, and L.L. Lanier. 2000. Retinoic acid-early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721. | |
|
Bakker, A.B.H., R.M. Hoek, A. Cerwenka, B. Blom, L. Lucian, T. McNeil, R. Murray, J.H. Phillips, J.D. Sedgwick, and L.L. Lanier. 2000. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13:345. | |
|
Ravetch, J.V. and L.L. Lanier. 2000. Immune inhibitory receptors. Science 290:84-89. | |
|
Wu, J., H. Cherwinski, T. Spies, J.H. Phillips, and L.L. Lanier. 2000. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J. Exp. Med. 192:1059-1067. | |
|
Lanier, L.L. 2001. A renaissance for the tumor immunosurveillance hypothesis. Nature Medicine 7:1178-1180. | |
|
Cerwenka A, Baron JL, and Lanier LL. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits NK cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98:11521. | |
|
Cerwenka, A., and L.L. Lanier. 2001. Natural killer cells, viruses and cancer. Nature Reviews Immunology 1:41-49. | |
|
Arase, H., T. Saito, J.H. Phillips, and L.L. Lanier. 2001. Cutting Edge: The mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (α2 integrin, very late antigen-2). J. Immunol. 167:1141-1144. | |
|
O'Callaghan, C.A., A. Cerwenka, B.E. Willcox, L.L. Lanier, and P.J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15:201-211. | |
|
Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and L.L. Lanier. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296:1323. | |
|
Ogasawara, K., S.K. Yoshinaga, and L.L. Lanier. 2002. Inducible costimulator costimulates cytotoxic activity and IFN-γ production in activated murine NK cells. J. Immunol. 169:3676-3685. | |
|
Lodoen, M., K. Ogasawara, J.A. Hamerman, H. Arase, J.P. Houchins, E.S. Mocarski, and L.L. Lanier. 2003. NKG2D-mediated NK cell protection against cytomegalovirus is impaired by gp40 modulation of RAE-1 molecules. J. Exp. Med. 197:1245. | |
|
Ogasawara, K. J.A. Hamerman, H. Hsin, S. Chikuma, H. Jordon, T. Chen, T. Pertel, C. Carnaud, J.A. Bluestone and L.L. Lanier. 2003. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18:41. | |
|
Zompi, S., J.A. Hamerman, K. Ogasawara, E. Schweighoffer, V.L.J. Tybulewicz, J.P. DiSanto, L.L. Lanier, and F. Colucci. 2003. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nature Immunology 4:565-572. | |
|
Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2004. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 173:3716-3724. | |
|
Rosen, D.B. M. Araki, J.A. Hamerman, T. Chen, T. Yamamura, and L.L. Lanier. 2004. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173:2470-2478. | |
|
Ogasawara, K., J.A. Hamerman, L.R. Ehrlich, H. Bour-Jordon, J.A. Bluestone, and L.L. Lanier. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20:757. | |
|
Lodoen, M., G. Abenes, S. Umamoto, J.P. Houchins, F. Liu, and L.L. Lanier. 2004. The cytomegalovirus m155 gene product subverts NK cell antiviral protection by disruption of H60-NKG2D interactions. J. Exp. Med. 200:1075. | |
|
Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2004. Cutting Edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J. Immunol. 172:2001-2005. | |
|
Lanier, L.L. 2005. NK cell recognition. Annu. Rev. Immunol, 23:225. | |
|
Richie Ehrlich, L.I., K. Ogasawara, J.A. Hamerman, R. Takaki, A. Zingoni, J.P. Allison, and L.L. Lanier. 2005. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J. Immunol. 174:1922-1931. | |
|
Takaki, R., Y. Hayakawa, A. Nelson, P.V. Sivakumar, S. Hughes, M.J. Smyth, and L.L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175:2167-2173. | |
|
Lodoen, M.B. and L.L. Lanier. 2005. Viral modulation of NK cell immunity. Nature Reviews Microbiology 3:59. | |
|
Desrosiers, M-P., A. Kielczewska, S.G. Adam, A.P. Makrigiannis, S. Lemieux, K. Morgan, J-C. Loredo-Osti, T. Pham, M.B. Lodoen, L.L. Lanier, and S.M. Vidal. 2005. Innate resistance to cytomegalovirus infection is associated with epistasis between activating natural killer receptor and MHC class I molecule. Nature Genetics 37:593. | |
|
Hamerman, J.A., N. K. Tchao, C.A. Lowell, and L.L. Lanier. 2005. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nature Immunology 6:579. | |
|
Ogasawara, K., J. Benjamin, R. Takaki, J.H. Phillips, and L.L. Lanier. 2005. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nature Immunology 6:938. | |
|
Routes, J.M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L.L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202:1477. | |
|
Rosen, D.B., J. Bettadapura, M. Alsharifi, P.A. Mathew, H.S. Warren, and L.L. Lanier. 2005. Cutting Edge: Lectin-like transcript-1 (LLT1) is a ligand for the inhibitory human NKR-P1A receptor. J. Immunol. 175:7796. | |
|
Chen, S., H. Kawashima, J.B. Lowe, L.L. Lanier, and M. Fukuda. 2005. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J. Exp. Med. 202:1679-1689. | |
|
Shiow, L.R., D.B. Rosen, N. Brdickova, Y. Xu, J. An, L.L. Lanier, J.G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-α/ƒÀ to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440:540-544. | |
|
Hamerman, J.A. and L.L. Lanier. 2006. Inhibition of immune responses by ITAM-bearing receptors. Science STKE volume 2006, issue 320, pp. re1. | |
|
Cao, W., D.B. Rosen, T. Ito, L. Bover, M. Bao, G. Watanabe, L. Zhang, L.L. Lanier, and Y-J. Liu. 2006. Plasmacytoid dendritic cell-specific receptor ILT7/FcεRIγ inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 203:1399-1405. | |
|
Hesslein, D.G.T., R. Takaki, M.L. Hermiston, A. Weiss, and L.L. Lanier. 2006. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc. Natl. Acad. Sci. USA 103:7012. | |
|
Hamerman, J.A., J.R. Jarjoura, M.B. Humphrey, M.C. Nakamura, W.E. Seaman, and L.L. Lanier. 2006. Cutting Edge: Inhibition of Toll-like receptor and Fc-receptor responses in macrophages by TREM-2 and DAP12. J. Immunol. 174:2051. | |
|
11/16/09 |
|
